InsiderTrades

Form 4 for ANGO ANGIODYNAMICS INC

Accepted 2024-08-02 00:00:00 ET · period of report 2024-07-17 · accession 0001140361-24-035597 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2024-08-02 2024-07-17+ ANGO Trowbridge Stephen A EVP, CFO F - Tax $7.31 -6,601 171.0K -4% -$48.3K
D 2024-08-02 2024-07-17 ANGO Trowbridge Stephen A EVP, CFO M - OptEx $0.00 +11.1K 177.6K +7% $0
D 2024-08-02 2024-07-17 ANGO Trowbridge Stephen A EVP, CFO M - OptEx $0.00 +14.8K 0 New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-07-17 F D 4,016 $7.40 173,596 D — — (F2) The exempt disposition of 4,016 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 21, 2021.
2 Common Common Stock 2024-07-17 M A 11,142 $0.00 177,612 D — — (F1) This acquisition of 11,142 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 21, 2021.
3 Common Common Stock 2024-07-19 F D 2,585 $7.18 171,011 D — — (F3) The exempt disposition of 2,585 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares of underlying restricted stock units granted to the reporting person on July 19, 2023.
4 Derivative Performance Right 2024-07-17 M A 14,817 $0.00 0 D — · — to — 14,817 Common Stock (F4) On July 21, 2021, the reporting person received a target grant of 14,817 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2022, 2023 and 2024 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 11,142 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.